Phospho-SNCA (Y133) Antibody

What is the biological significance of Y133 phosphorylation in alpha-synuclein?

Y133 phosphorylation plays a pivotal role in alpha-synuclein aggregate clearance through two primary mechanisms. First, it supports the protective S129 phosphorylation that promotes autophagic clearance of protein inclusions. Second, it directly contributes to proteasome-mediated clearance independent of S129 phosphorylation . Mass spectrometry analysis has revealed almost complete co-phosphorylation of S129 and Y133 in both wild-type aSyn (100% for S129, 99.8% for Y133) and A30P mutant (100% for both sites), suggesting a functional relationship between these modifications . The importance of this residue is further highlighted by its location in the C-terminal region, where numerous disease-associated post-translational modifications occur. Researchers investigating aSyn pathology should consider Y133 phosphorylation as a key regulatory mechanism for protein homeostasis rather than merely a marker of pathology.

What methods are available for validating the specificity of Phospho-SNCA (Y133) antibodies?

A comprehensive validation approach for Phospho-SNCA (Y133) antibodies should involve multiple complementary techniques:

• Western blotting with recombinant proteins: Test antibodies against wild-type aSyn, aSyn phosphorylated only at Y133, and aSyn with multiple PTMs (including Y133 phosphorylation) .

• Mass spectrometry confirmation: Use trypsin or AspN digestions (or both) to achieve 100% sequence coverage when confirming phosphorylation sites detected by antibodies .

• Knockout controls: Always include alpha-synuclein knockout (SNCA KO) samples to identify non-specific binding .

• Dot/slot blot analysis: This provides a rapid screening method for antibody specificity against different aSyn proteoforms .

• Immunohistochemistry: Compare staining patterns between wild-type and SNCA KO brain sections in multiple regions (cortex, hippocampus, substantia nigra) .

• Epitope mapping: Determine precise binding regions using peptide arrays or truncated recombinant proteins to understand potential cross-reactivity issues .

When antibodies show cross-reactivity or detect non-specific bands in knockout samples, these should be thoroughly documented to prevent misinterpretation of experimental results.

How does Y133 phosphorylation interact with S129 phosphorylation in alpha-synuclein pathology?

The relationship between Y133 and S129 phosphorylation involves complex bidirectional interactions that significantly impact alpha-synuclein pathology. Research has revealed that Y133 is required for protective S129 phosphorylation, suggesting a hierarchical relationship where Y133 modification precedes and enables S129 phosphorylation . Mass spectrometry data shows nearly complete co-phosphorylation of these sites, with probability scores of 100% for S129 and 99.8% for Y133 in wild-type alpha-synuclein .

This interplay has important implications for cellular clearance mechanisms. While S129 phosphorylation primarily promotes autophagic clearance, Y133 appears to support both autophagic (through enabling S129 phosphorylation) and proteasomal clearance pathways . The dual functionality makes Y133 phosphorylation a critical regulatory node in alpha-synuclein proteostasis.

Investigation of this interaction requires careful experimental design. Researchers should consider using site-directed mutagenesis (Y133F mutants) to abolish phosphorylation capability at this site while preserving protein structure, allowing for examination of downstream effects on S129 phosphorylation and aggregation dynamics. Additionally, time-course experiments may reveal the sequential ordering of these modifications in response to cellular stressors.

What experimental approaches are recommended for distinguishing between different C-terminal modifications of alpha-synuclein?

Distinguishing between C-terminal modifications of alpha-synuclein presents significant challenges due to their proximity and potential co-occurrence. A multi-modal approach is recommended:

• Combined proteolytic digestion: Employ both trypsin and AspN digestions to achieve 100% sequence coverage, allowing for precise identification of modifications at specific residues .

• Targeted mass spectrometry: Use parallel reaction monitoring (PRM) or multiple reaction monitoring (MRM) to increase sensitivity for specific modified peptides, especially when studying brain tissue samples with limited amounts of modified protein.

• Panel of highly specific antibodies: Utilize antibodies targeting different modifications with validated specificity profiles. For example, antibodies specifically developed against doubly phosphorylated peptides (e.g., pY125/pS129) may be adapted for studies involving Y133 phosphorylation.

• 2D gel electrophoresis: Separate proteins first by isoelectric point and then by molecular weight to resolve different post-translationally modified forms before immunoblotting.

• Proximity ligation assays: For tissue samples, this technique can detect when two modifications occur in very close proximity, potentially on the same protein molecule.

When analyzing data, researchers should recognize that the absence of signal using one approach does not conclusively demonstrate the absence of a modification, as detection limitations may vary across techniques.

How do nitration and phosphorylation of Y133 differentially affect alpha-synuclein aggregation and toxicity?

Y133 can undergo either phosphorylation or nitration, with dramatically different functional consequences for alpha-synuclein. While phosphorylation at Y133 promotes aggregate clearance and exhibits protective properties, nitration of C-terminal tyrosine residues, including Y133, contributes to increased pathogenicity .

Mass spectrometry analysis has identified nitration of all three C-terminal tyrosines (Y125, Y133, Y136) in wild-type alpha-synuclein, whereas nitration in the A30P mutant was restricted to Y125 and absent at Y133 and Y136 . This differential nitration pattern correlates with variations in toxicity between wild-type and A30P alpha-synuclein in experimental models.

The mechanistic distinction appears to involve different cellular responses to these modifications:

• Phosphorylated Y133 promotes both proteasomal clearance and enables protective S129 phosphorylation for autophagy.

• Nitrated Y133 may interfere with these clearance mechanisms, contributing to protein accumulation.

• Alpha-synuclein can form di-tyrosine dimers through covalent crosslinking, which may represent a cellular detoxification pathway, as evidenced by higher dimer formation in the less toxic A30P mutant compared to wild-type protein .

Experimental approaches to study these differential effects should include site-specific incorporation of modified amino acids using nonsense suppression technology or protein semi-synthesis to generate homogeneously modified alpha-synuclein for functional studies.

What are the methodological considerations when developing antibodies against phosphorylated Y133 in the presence of neighboring PTMs?

Developing antibodies that specifically recognize phosphorylated Y133 in the presence of neighboring PTMs requires careful strategic planning:

• Antigen design: Immunizing peptides should span beyond the immediate vicinity of Y133 (approximately residues 128-138) to ensure proper epitope recognition. Consider developing antibodies using doubly modified peptides (e.g., with combinations of Y133 phosphorylation and other nearby modifications) to generate antibodies insensitive to neighboring PTMs .

• Screening strategy: Initial screening should include a diverse panel of alpha-synuclein proteoforms with various modifications to identify clones with the desired specificity profile. This includes testing against:

  • Singly phosphorylated aSyn (pY133 only)

  • Multiply phosphorylated aSyn (pY133 with pS129 and/or pY125)

  • Nitrated forms (nY133)

  • Truncated variants (truncation at 135 or 133)

• Cross-reactivity assessment: Thoroughly evaluate potential cross-reactivity with other phosphorylated proteins, particularly those containing similar phospho-tyrosine motifs. This can be accomplished through proteomic approaches comparing immunoprecipitation results from wild-type and SNCA knockout samples .

• Validation in complex samples: Test antibodies in brain tissue from synucleinopathy models and human patients, comparing with alpha-synuclein knockout controls to identify any non-specific signals .

This methodical approach increases the likelihood of developing antibodies that accurately capture the biochemical diversity of phosphorylated alpha-synuclein at Y133 in disease conditions.

What are the essential controls for immunohistochemistry when using Phospho-SNCA (Y133) antibodies?

When performing immunohistochemistry with Phospho-SNCA (Y133) antibodies, the following controls are essential to ensure reliable and interpretable results:

• Alpha-synuclein knockout tissue: This represents the gold standard negative control, as any signal observed in knockout tissue indicates non-specific binding. Evidence shows that even well-characterized phospho-specific antibodies can produce background staining in knockout samples .

• Dephosphorylation controls: Treat serial sections with lambda phosphatase to remove phosphate groups, which should eliminate specific phospho-Y133 signal while preserving total alpha-synuclein immunoreactivity.

• Peptide competition: Pre-absorb the antibody with excess phospho-Y133 peptide to block specific binding sites, which should eliminate specific signal.

• Multiple brain regions: Assess staining patterns across different brain regions (cortex, hippocampus, substantia nigra) as background staining may vary regionally .

• Multiple antibody validation: Whenever possible, confirm findings using at least two antibodies recognizing different epitopes containing phosphorylated Y133.

• Post-fixation validation: Validate antibody performance with different fixation methods, as some epitopes may be masked or altered by certain fixatives.

When analyzing results, researchers should pay careful attention to somatic staining patterns, as non-specific cell body staining has been observed with some phospho-specific antibodies across both wild-type and knockout tissue .

How can mass spectrometry be used to complement antibody-based detection of Y133 phosphorylation?

Mass spectrometry provides powerful complementary approaches to antibody-based detection of Y133 phosphorylation, offering several advantages:

• Unbiased detection: Mass spectrometry can simultaneously identify multiple PTMs on alpha-synuclein without relying on epitope availability or antibody specificity.

• Stoichiometry determination: Quantitative mass spectrometry allows for determination of the relative abundance of different modified forms, including the proportion of alpha-synuclein phosphorylated at Y133.

• PTM co-occurrence analysis: This approach can reveal whether Y133 phosphorylation co-occurs with other modifications on the same protein molecule, providing insights into modification patterns that may have functional significance.

Recommended methodological approaches include:

• Combined proteolytic digestions: Using both trypsin and AspN digestions provides 100% sequence coverage, ensuring comprehensive PTM identification .

• PTM enrichment strategies: Phosphopeptide enrichment using titanium dioxide (TiO₂) or immobilized metal affinity chromatography (IMAC) increases detection sensitivity for low-abundance phosphorylated species.

• Targeted approaches: Parallel reaction monitoring (PRM) or multiple reaction monitoring (MRM) can significantly enhance sensitivity for specific phosphorylated peptides.

• Probability scoring: Apply algorithms such as phosphoRS to calculate probability scores for potential phosphorylation sites, as demonstrated in Table 1 from search result , where Y133 phosphorylation was identified with 99.8% probability in wild-type alpha-synuclein.

What experimental design is recommended for studying the functional consequences of Y133 phosphorylation?

To effectively study the functional consequences of Y133 phosphorylation, a multi-faceted experimental approach is recommended:

• Site-directed mutagenesis: Create Y133F mutants (preventing phosphorylation) and Y133E mutants (phosphomimetic) to study the effects of phosphorylation status on alpha-synuclein aggregation, clearance, and toxicity.

• Cell-based models: Utilize neuronal cell models expressing wild-type or mutant (Y133F, Y133E) alpha-synuclein to assess:

  • Aggregate formation using fluorescence microscopy

  • Protein clearance rates through pulse-chase experiments

  • Autophagy and proteasome activity measurements

  • Cell viability and stress response

• In vitro phosphorylation: Identify and characterize kinases responsible for Y133 phosphorylation to develop tools for manipulating this modification. This may involve screening tyrosine kinases and performing in vitro kinase assays with recombinant alpha-synuclein.

• Interaction studies: Employ co-immunoprecipitation or proximity ligation assays to identify proteins that preferentially interact with phosphorylated Y133 alpha-synuclein compared to non-phosphorylated forms.

• Animal models: Develop transgenic mouse models expressing Y133F alpha-synuclein to assess the in vivo consequences of blocking this phosphorylation site, focusing on:

  • Alpha-synuclein aggregation patterns

  • Neurodegeneration markers

  • Behavioral phenotypes

  • Response to stressors that induce synucleinopathy

This comprehensive approach will help elucidate the role of Y133 phosphorylation in the complex interplay between different alpha-synuclein modifications and their impact on protein homeostasis and neurodegeneration.

How does understanding Y133 phosphorylation contribute to therapeutic strategies for synucleinopathies?

Understanding Y133 phosphorylation of alpha-synuclein offers several promising avenues for therapeutic intervention in synucleinopathies:

• Targeted kinase modulation: Identifying and targeting the kinases responsible for Y133 phosphorylation could enhance this protective modification. Unlike other phosphorylation sites with context-dependent effects, Y133 phosphorylation appears consistently associated with aggregate clearance .

• Nitrative stress protection: The interplay between Y133 phosphorylation and nitration suggests that reducing nitrative stress could shift the balance toward the protective phosphorylated form. Research has shown that the yeast flavohemoglobin Yhb1 and its human homolog neuroglobin (NGB) protect against nitrative stress and alpha-synuclein aggregation . This identifies neuroglobin as a potential therapeutic target, as its overexpression protected against alpha-synuclein inclusion formation in mammalian cells .

• PTM-specific immunotherapy: Antibodies specifically targeting pathological forms of alpha-synuclein are being explored as therapeutic agents. Understanding the precise epitopes and modification patterns, including Y133 phosphorylation status, could inform the development of more effective immunotherapies that specifically target pathological species while sparing functional forms.

• Clearance pathway enhancement: Since Y133 phosphorylation promotes both autophagic and proteasomal clearance mechanisms , therapeutic strategies enhancing these pathways may be particularly effective when Y133 phosphorylation is intact.

The dual role of Y133 in supporting both S129-dependent and S129-independent clearance mechanisms makes this modification a particularly valuable target for therapeutic development, potentially offering broader protection against alpha-synuclein accumulation than approaches targeting single clearance pathways.

What are the current gaps in our understanding of Y133 phosphorylation in alpha-synuclein biology?

Despite significant advances, several critical knowledge gaps remain regarding Y133 phosphorylation of alpha-synuclein:

• Enzymatic regulation: The kinases and phosphatases that regulate Y133 phosphorylation remain poorly characterized. Unlike S129 phosphorylation, which has been extensively studied, the enzymatic machinery controlling Y133 phosphorylation requires further investigation.

• Temporal dynamics: The sequence of modifications during alpha-synuclein aggregation and pathology progression is not fully understood. While Y133 phosphorylation appears to precede and enable S129 phosphorylation , the timing relative to other modifications and aggregation events requires clarification.

• Regional and cellular variations: Research has not adequately addressed whether Y133 phosphorylation patterns differ across brain regions or cell types, which could explain selective vulnerability in synucleinopathies.

• Pathological relevance in human tissue: Most studies have utilized cellular or animal models. Comprehensive analysis of Y133 phosphorylation in human pathological samples from different synucleinopathies (Parkinson's disease, dementia with Lewy bodies, multiple system atrophy) would provide critical insights into disease-specific patterns.

• Structural consequences: How Y133 phosphorylation affects alpha-synuclein's three-dimensional structure, especially in the context of the protein's intrinsically disordered nature, remains to be fully elucidated.

Addressing these knowledge gaps will require developing more specific tools, including antibodies that can detect Y133 phosphorylation regardless of neighboring modifications , and applying advanced structural biology techniques to characterize the conformational effects of this modification.